Parabilis Medicines

Parabilis Medicines (formerly FogPharma) integrates AI and physics-based computational methods with non-canonical amino acid chemistry to discover Helicon peptide therapeutics. Its lead program zolucatetide (FOG-001) is a beta-catenin inhibitor for desmoid tumors — targeting a pathway previously considered undruggable. The company raised $305M in January 2026, one of the largest biotech financings of early 2026.

$305M+

Total raised

Helicon platform integrates AI and physics-based computational methods with non-canonical amino acid chemistry. Designs cell-permeable peptides that can drug intracellular protein-protein interactions, reaching targets inaccessible to conventional small molecules and biologics.